How should measles be managed, including isolation precautions, supportive care, vitamin A supplementation, and post‑exposure prophylaxis?

Management of Measles

All patients with confirmed or suspected measles require immediate airborne isolation, mandatory vitamin A supplementation, supportive care for complications, and consideration of post-exposure prophylaxis for exposed contacts. 1

Immediate Isolation and Infection Control

Implement strict airborne precautions immediately upon suspicion of measles:

• Place the patient in a negative-pressure airborne isolation room; if unavailable, use a private room with the door closed 2
• All healthcare personnel entering the room must wear N95 respirators regardless of immunity status 1, 2
• Only staff with documented measles immunity should provide direct patient care 2
• Maintain isolation for at least 4 days after rash onset, as patients are contagious from 4 days before through 4 days after rash appearance 1, 2
• The patient should wear a medical-type mask upon arrival to reduce droplet dissemination 2

Healthcare Worker Management

• Exposed healthcare workers without documented immunity must be excluded from work from day 5 through day 21 post-exposure 1, 2
• Workers who develop measles must remain excluded until at least 4 days after rash onset 2
• Administer the first dose of MMR vaccine immediately to non-immune exposed staff 2
• Note that vaccine failure occurs in approximately 1% of vaccinated individuals, justifying universal respiratory protection 2

Vitamin A Supplementation (Mandatory for All Patients)

Vitamin A supplementation is the only evidence-based intervention proven to reduce measles mortality and must be administered to all patients with clinical measles:

Standard Dosing Protocol

• For patients ≥12 months (including adults): 200,000 IU orally on day 1 1, 2
• For infants <12 months: 100,000 IU orally on day 1 1, 2
• Do not administer if the patient received vitamin A supplementation in the previous month 1

Enhanced Two-Dose Regimen for Complicated Measles

• Administer an identical second dose on day 2 when any of the following complications are present: pneumonia, otitis media, croup, diarrhea with moderate or severe dehydration, or neurological problems 1, 2
• This regimen reduces overall mortality by 64% (RR 0.36) and pneumonia-specific mortality by 67% (RR 0.33), with an 82% mortality reduction in children <2 years (RR 0.18) 1

Extended Protocol for Vitamin A Deficiency Eye Signs

• If eye symptoms are present (xerosis, Bitot's spots, keratomalacia, or corneal ulceration), administer:
  • 200,000 IU on day 1
  • 200,000 IU on day 2
  • A third dose of 200,000 IU at 1-4 weeks later 1, 2
• For infants <12 months with eye symptoms, use half doses (100,000 IU) 1, 2

Follow-Up Supplementation

• In communities with high prevalence of vitamin A deficiency, provide additional oral vitamin A supplementation every 3 months after completing acute treatment 1

Supportive Care and Complication Management

Treatment is primarily supportive, as no specific antiviral therapy is available:

Fever Management

• Administer acetaminophen or ibuprofen for fever control 1
• Aspirin is contraindicated in children younger than 16 years 1

Hydration and Diarrhea

• Provide adequate hydration, preferably with oral rehydration therapy (ORT), for patients with diarrhea 1, 2

Secondary Bacterial Infections

• Treat secondary bacterial pneumonia or acute lower respiratory infection with standard antibiotic therapy per local protocols 1, 2
• Provide appropriate antibiotic therapy for otitis media when indicated 1, 2

Nutritional Monitoring

• Assess and monitor nutritional status of every measles patient 1, 2
• Enroll in supplemental feeding programs in resource-limited settings when needed 1

Hospital Admission Criteria

• Immediate hospital referral is required for any danger sign: respiratory distress (markedly raised respiratory rate, grunting, intercostal recession, breathlessness with chest signs, or cyanosis), severe dehydration, altered level of consciousness, or signs of septicemia (extreme pallor, hypotension, floppy infant) 1

Post-Exposure Prophylaxis (PEP)

The choice between MMR vaccine and immune globulin depends on timing of intervention and patient characteristics:

MMR Vaccine (Preferred for Eligible Contacts)

• Administer MMR vaccine within 72 hours of exposure to susceptible contacts ≥6 months of age (excluding pregnant persons, immunocompromised individuals, and those with vaccine contraindications) 1, 2
• Vaccination within this window may prevent infection or attenuate disease severity 1, 2
• For routine vaccination, two doses are recommended: first at age 12-15 months, second at age 4-6 years 3

Immune Globulin (IG) for High-Risk Contacts

IG is recommended for susceptible household contacts at increased risk of severe complications who cannot receive vaccine:

Standard Dosing for General Contacts

• Administer intramuscular IG at 0.25 mL/kg (maximum 15 mL) as soon as possible, ideally within 6 days of exposure 1, 2
• This dose applies to infants ≤12 months and pregnant persons 1

Enhanced Dosing for Immunocompromised Contacts

• Administer intramuscular IG at 0.5 mL/kg (maximum 15 mL) within 6 days of exposure 1, 2
• For infants <6 months, if injection volume is not a major concern, use 0.5 mL/kg 4

Alternative IVIg Dosing

• When injection volume is a major concern or for recipients ≥30 kg, intravenous immunoglobulin (IVIg) can be provided at 400 mg/kg 4
• Recipients of IVIg should have received at least 100 mg/kg within 3 weeks before exposure to ensure adequate protection 1

Important Timing Considerations

• After IG administration, delay measles vaccination for 5-6 months to avoid interference from passively acquired antibodies 1
• When IG is given, monitor contacts for 28 days because passive antibodies can prolong the incubation period 2

Critical Pitfall to Avoid

• Do not use immune globulin for outbreak control; it is indicated only for individual post-exposure prophylaxis 1
• IG is not completely effective; exposed medical personnel should be removed from patient contact days 5-21 after exposure even if they receive prophylaxis 3

Diagnostic Confirmation

Laboratory confirmation should be obtained during the first clinical encounter:

• Obtain serum measles IgM antibody testing during the first visit 1
• If negative within 72 hours of rash onset, obtain another specimen at least 72 hours after rash onset 1
• Alternative specimens include throat or nasopharyngeal swabs, urine, or oral fluid for viral RNA detection 5

Special Populations

Pregnant Women

• Pregnant women exposed to measles who are not yet symptomatic should receive IG 0.25 mL/kg (maximum 15 mL) within 6 days of exposure 1
• Once symptomatic, provide supportive care with vitamin A supplementation 1

Immunocompromised Patients

• Should receive IG 0.5 mL/kg (maximum 15 mL) if exposed, regardless of vaccination status 2
• Consider ribavirin in severe cases, though no FDA-approved antiviral exists 6

Travelers

• Persons born during or after 1957 who travel abroad should have received two doses of measles vaccine if they lack other evidence of immunity 3
• Before international travel, infants aged 6-11 months should receive a single dose 3

Common Pitfalls and Caveats

• Do not extrapolate measles treatment guidelines (including vitamin A supplementation) to rubella, as these are distinct diseases with different pathophysiology and complication profiles 7
• Maintain full isolation for 4 days after rash onset and use N95 respirators instead of regular surgical masks 2
• Do not forget vitamin A supplementation, which is the only evidence-based intervention to reduce measles mortality 2
• Recognize that approximately 5-15% of vaccinees develop fever ≥103°F (39.4°C) between days 5-12 post-vaccination, and approximately 5% develop rashes 3